Literature DB >> 15121377

Conservation of eyes with choroidal melanoma by a multimodality approach to treatment: an audit of 1632 patients.

Bertil Damato1, Karin Lecuona.   

Abstract

OBJECTIVE: To report on conservation of eyes with choroidal melanoma with a multimodality approach to treatment.
DESIGN: Prospective, noncomparative, interventional case series. PARTICIPANTS: All 1632 patients with choroidal melanoma treated at a single center between 1993 and 2002. INTERVENTION: Primary enucleation (35%), brachytherapy (31.3%), proton beam radiotherapy (16.7%), transscleral local resection (11.0%), endoresection (3.7%), transpupillary thermotherapy (2.5%), and photocoagulation (0.1%). MAIN OUTCOME MEASURES: Primary and secondary enucleation.
RESULTS: Logistic regression showed the main predictive factors for primary enucleation to be: age more than 60 years (odds ratio [OR], 2.4; 95% confidence interval [CI], 1.8%-3.2%); reduced visual acuity (OR, 2.5; 95% CI, 1.9%-3.2%); posterior extension close to or involving the optic disc and fovea (OR, 1.7; 95% CI, 1.2%-2.4%); circumferential spread around the ciliary body, iris, or angle (OR, 3.1; 95% CI, 1.8%-5.5%); basal tumor diameter (OR, 3.5; 95% CI, 2.4%-5.0%); and tumor height (OR, 6.3; 95% CI, 4.5%-8.9%). After conservative treatment, the actuarial rate of secondary enucleation was 11.1% at 5 years (95% CI, 8.6%-13.6%). Cox multivariate analysis indicated the factors independently predicting secondary enucleation as: nasal/midline tumor location (risk ratio [RR], 2.6; 95% CI, 1.6%-4.4%); disc involvement (RR, 2.2; 95% CI, 1.2%-4.1%); tumor diameter (RR, 1.2; 95% CI, 1.0%-1.5%); and tumor thickness (RR, 1.8; 95% CI, 1.5%-2.1%).
CONCLUSIONS: With a multimodality approach to treatment, 65% of patients underwent conservative treatment, and of them, 89% retained their eye at 5 years, with success depending on tumor diameter, tumor thickness, disc involvement, and coronal location.

Entities:  

Mesh:

Year:  2004        PMID: 15121377     DOI: 10.1016/j.ophtha.2003.09.028

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  15 in total

1.  Differences in uveal melanomas between men and women from the British Isles.

Authors:  B E Damato; S E Coupland
Journal:  Eye (Lond)       Date:  2011-11-11       Impact factor: 3.775

2.  Transscleral local resection versus iodine brachytherapy for uveal melanomas that are large because of tumour height.

Authors:  Ilkka Puusaari; Bertil Damato; Tero Kivelä
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-11-18       Impact factor: 3.117

3.  Progress in the management of patients with uveal melanoma. The 2012 Ashton Lecture.

Authors:  B Damato
Journal:  Eye (Lond)       Date:  2012-06-29       Impact factor: 3.775

4.  Comparison between patient-reported outcomes after enucleation and proton beam radiotherapy for uveal melanomas: a 2-year cohort study.

Authors:  Laura Hope-Stone; Stephen L Brown; Heinrich Heimann; Bertil Damato
Journal:  Eye (Lond)       Date:  2019-04-15       Impact factor: 3.775

5.  miRNA profiling in vitreous humor, vitreal exosomes and serum from uveal melanoma patients: Pathological and diagnostic implications.

Authors:  Marco Ragusa; Cristina Barbagallo; Luisa Statello; Rosario Caltabiano; Andrea Russo; Lidia Puzzo; Teresio Avitabile; Antonio Longo; Mario D Toro; Davide Barbagallo; Hadi Valadi; Cinzia Di Pietro; Michele Purrello; Michele Reibaldi
Journal:  Cancer Biol Ther       Date:  2015-05-07       Impact factor: 4.742

Review 6.  Predictors of emotional distress in uveal melanoma survivors: a systematic review.

Authors:  Cari Davies; Stephen Lloyd Brown; Peter Fisher; Laura Hope-Stone; Debra Fisher; Andrew Morgan; Mary Gemma Cherry
Journal:  Eye (Lond)       Date:  2022-08-08       Impact factor: 4.456

Review 7.  Does ocular treatment of uveal melanoma influence survival?

Authors:  B Damato
Journal:  Br J Cancer       Date:  2010-07-27       Impact factor: 7.640

8.  Transscleral resection without hypotensive anaesthesia vs iodine-125 plaque brachytherapy in the treatment of choroidal melanoma.

Authors:  J M Caminal; N Padrón-Pérez; L Arias; C Masuet-Aumatell; C Gutiérrez; J M Piulats; J Pera; J Català; M J Rubio; J Arruga
Journal:  Eye (Lond)       Date:  2016-04-01       Impact factor: 3.775

Review 9.  Personalized treatment of uveal melanoma.

Authors:  B Damato; H Heimann
Journal:  Eye (Lond)       Date:  2012-11-23       Impact factor: 3.775

10.  Cost-effectiveness of proton beam therapy for intraocular melanoma.

Authors:  James P Moriarty; Bijan J Borah; Robert L Foote; Jose S Pulido; Nilay D Shah
Journal:  PLoS One       Date:  2015-05-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.